GT Biopharma 미래 성장

Future 기준 확인 0/6

현재 GT Biopharma 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	28.3%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 GT Biopharma 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NasdaqCM:GTBP - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
9/30/2024	N/A	-12	-12	-12	N/A
6/30/2024	N/A	-11	-12	-12	N/A
3/31/2024	N/A	-10	-10	-10	N/A
12/31/2023	N/A	-8	-9	-9	N/A
9/30/2023	N/A	-10	-11	-11	N/A
6/30/2023	N/A	-15	-12	-12	N/A
3/31/2023	N/A	-16	-13	-13	N/A
12/31/2022	N/A	-21	-15	-15	N/A
9/30/2022	N/A	-33	-15	-15	N/A
6/30/2022	N/A	-32	-16	-16	N/A
3/31/2022	N/A	-34	-17	-17	N/A
12/31/2021	N/A	-58	-16	-16	N/A
9/30/2021	N/A	-46	-14	-14	N/A
6/30/2021	N/A	-44	-12	-12	N/A
3/31/2021	N/A	-56	-11	-11	N/A
12/31/2020	N/A	-28	-7	-7	N/A
9/30/2020	N/A	-23	-6	-6	N/A
6/30/2020	N/A	-50	-5	-5	N/A
3/31/2020	N/A	-36	-3	-3	N/A
12/31/2019	N/A	-39	-4	-4	N/A
9/30/2019	N/A	-41	-4	-4	N/A
6/30/2019	N/A	-247	-7	-7	N/A
3/31/2019	N/A	-254	-7	-7	N/A
12/31/2018	N/A	-259	-11	-11	N/A
9/30/2018	N/A	-261	-12	-12	N/A
6/30/2018	N/A	-156	N/A	-10	N/A
3/31/2018	N/A	-149	N/A	-9	N/A
12/31/2017	N/A	-144	N/A	-5	N/A
9/30/2017	N/A	-141	N/A	-3	N/A
6/30/2017	N/A	-14	N/A	-2	N/A
3/31/2017	N/A	-10	N/A	-2	N/A
12/31/2016	N/A	10	N/A	-2	N/A
9/30/2016	N/A	-14	N/A	-3	N/A
6/30/2016	N/A	-12	N/A	-3	N/A
3/31/2016	0	14	N/A	-3	N/A
12/31/2015	0	-21	N/A	-5	N/A
9/30/2015	0	-14	N/A	-5	N/A
6/30/2015	0	-17	N/A	-5	N/A
3/31/2015	0	-44	N/A	-3	N/A
12/31/2014	0	-23	N/A	-2	N/A
9/30/2014	0	-5	N/A	-1	N/A
6/30/2014	0	-1	N/A	0	N/A
3/31/2014	0	-1	N/A	0	N/A
12/31/2013	0	-1	N/A	0	N/A

애널리스트 미래 성장 예측

수입 대 저축률: GTBP 의 예상 수익 증가율이 절약률( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: GTBP 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: GTBP 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: GTBP 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: GTBP 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: GTBP 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

GT Biopharma 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target decreased to US$4.00

Price target decreased to US$17.33

Price target decreased to US$17.33

Price target increased to US$25.33

Price target increased to US$25.33

Recent updates

GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces CFO Changes

New major risk - Shareholder dilution

GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million.

New major risk - Financial position

GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Share price stability

GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nasdaq Listing Qualifications Department Determines the GT Biopharma's Eligibility for an Additional 180 Calendar Day Period, or Until February 20, 2024, to Regain Compliance

New major risk - Revenue and earnings growth

New major risk - Market cap size

GT Biopharma, Inc. Announces Board Changes

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee

Price target decreased to US$4.00

High number of new and inexperienced directors

GT Biopharma files for $150M mixed shelf offering

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650

GT Biopharma GAAP EPS of -$0.10 beats by $0.07

GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index

GT Biopharma, Inc. Appoints Alan L. Urban to Fill Vacant Seat on Board

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

GT Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$17.33

High number of new and inexperienced directors

GT Biopharma, Inc. Announces CEO Changes

GT Biopharma, Inc Appoints Manu Ohri as Chief Financial Officer

Price target decreased to US$17.33

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Price target increased to US$25.33

High number of new and inexperienced directors

GT Biopharma Announces Updated Positive Safety Data from Phase 1 GTB-3550 Monotherapy Trike Trial an Investigational Immunotherapy for Refractory Cancers to Be Presented At ESMO Congress 2021

GT Biopharma, Inc. Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies

GT Biopharma, Inc. announced delayed 10-Q filing

GT Biopharma Provides Second Quarter 2021 Business Update

Price target increased to US$25.33

GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results

Getting To Know GT Biopharma

GT Biopharma, Inc. Announces Update on the Commencement of the GTB-3550 Trike Monotherapy Phase 2 Clinical Trial and Solid Tumor Trike Product Candidates

GT Biopharma names Gregory Berk Chief Medical Officer

GT Biopharma, Inc. announced delayed annual 10-K filing

GT Biopharma, Inc. Updates Interim GTB-3550 Trike™ Clinical Trial Results

GT Biopharma, Inc. Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

GT Biopharma, Inc. Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE, a Novel NK Cell Therapeutic Cancer Treatment

Gt Biopharma, Inc. Sign an Expanded GMP Manufacturing Agreement with Cytovance Biologics

GT Biopharma, Inc. has completed a Composite Units Offering in the amount of $23.65 million.

GT Biopharma, Inc. Announces Board Changes

GT Biopharma Announces Eighth Patient Begins Treatment of GTB-3550

GT Biopharma, Inc. Announces TriKE™ for the Treatment of Breast and GI Cancers

Gt Biopharma, Inc. and Cytovance Reaches Agreement for License Rights to Use Certain Bacterial and Mammalian Cell Lines and for GMP Manufacturing Services Performed to Date Regarding the Company's Trike™ Product Candidates

Dr. Greg Berk, M.D. Joins Board of Directors of GT Biopharma, Inc

GT Biopharma, Inc. Appoints Michael Handelman as Chief Financial Officer

GT Biopharma, Inc. Announces Advisory Board Appointments

GT Biopharma, Inc. announced that it has received $0.25 million in funding

GT Biopharma, Inc. announced that it has received $5.607 million in funding

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견